Dimitris Papoutsakis In remembrance

Lucky you, Fadi. With this lineup, I surely would have liked to be there! But for anyone in the Cambridge, MA area, this is a great chance to learn more about the use of #metabolomics and #multiomics in pharmaceutical research. Registration is free. Just follow the link in Fadi's post. #health #research #pharma

6

Good to see further data from Inflection Biosciences Ltd showcasing the potential for dual PIM/PI3K inhibitor IBL-202 in peripheral T-cell lymphoma (PTCL), an indication with ongoing unmet medical need. Data shows IBL-202 to be more potent in pre-clinical models versus combination of PI3K therapy copanlisib with PIM inhibitor AZD1208. Well done to the team at Universitätsmedizin Göttingen.

28

New research from the Center for Integration of Science and Industry at Bentley University show that differences between the financial structures of large pharmaceutical producers and smaller, emerging biotechnology companies creates synergies that contribute to the pipeline of new, innovative products in response to reductions in drug prices anticipated under the #InflationReductionAct (#IRA). A paper in the journal @Clinical Trials titled “Modeling impact of Inflation Reduction Act price negotiations on new drug pipeline considering differential contributions of large and small #biopharmaceutical companies,” showed that there was no empirical eviddence for a relationship between revenue and R&D spending in #biotechnology companies, which currently originate most new drugs and sponsor the majority of all clinical trials and rely on the proceeds of equity offerings for a substantial fraction of their innovatoin capital. A second working paper Institute for New Economic Thinking demonstrated that #investment in equity offerings and #valuation of biotechnnology companies are no associated with changes in indices of either #consumerprice or #producerprice for #prescription drugs. We conclude that “Pharmaceutical innovation is not adequately described by conventional economic theories that fail to account for the distinct business models of small, science-based biotechnology companies." and that "...established management and investment practices could preserve both the industry’s profits and current levels of drug approvals in face of the reductions in drug price anticipated by the Inflation Reduction Act.” Center for Integration of Science and Industry at Bentley University Bentley University Center for Health and Business West Health Policy Center Institute for New Economic Thinking #innovation, #pharmaceutical, #drugprices, #drugdiscovery, #drugdevelopment, #clinicaltrials, #investment, #valuation,

7

In an exclusive interview with The American Bazaar, Dr. Atul Varadhachary, Managing Partner at Fannin Innovation, shares insights into the challenges and strategies of early-stage biotech investment. With a focus on bridging the gap between groundbreaking scientific discoveries and successful commercialization, Dr. Varadhachary discusses Fannin’s unique model, the importance of talent development, and their journey to launching pioneering companies like Procyrion, Inc., Radiomer Therapeutics and Pulmotect, Inc. Read more about how Fannin is shaping the future of biotech in Houston and beyond. https://lnkd.in/e6pRkPbT

17

Check out our paper in the Journal of Medicinal Chemistry: “Discovery of Clinical Candidate PF-06648671: A Potent γ-Secretase Modulator for the Treatment of Alzheimer’s Disease”. We are grateful to everyone at Pfizer who contributed to this program over the years – especially to Christopher am Ende, Todd Butler, and Doug Johnson who were instrumental in getting this manuscript over the finish line. For those of you in the drug hunting community who may not be familiar with the pharmacological distinction between γ-secretase inhibitors (GSIs) and γ-secretase modulators (GSMs), here is a brief summary: - γ-Secretase Inhibitors (GSIs): This older class of compounds binds to the active site (or to an allosteric site) on the presenilin subunit of the γ-secretase complex resulting in inhibition of the enzyme. In addition to blocking formation of all forms of amyloid beta (Aβ) peptides, this approach also inhibits processing of many other substrates (including the Notch receptor) that are critical for normal cellular functions. Several γ-secretase inhibitors were advanced into clinical trials for Alzheimer’s disease quite some years ago, but these trials were terminated due to on-target toxicity. - γ-Secretase Modulators (GSMs): These compounds have a very different pharmacological profile compared to the GSIs. GSMs also bind to the presenilin subunit, but at allosteric sites that are distinct from those of the inhibitors. Rather than inhibiting the enzyme, GSMs modulate the enzymatic function and change the processivity to reduce formation of the longer, insoluble and neurotoxic Aβ peptides (including Aβ42) while increasing formation of the shorter, more soluble peptides, Aβ37 and Aβ38. Meanwhile, total Aβ remains unchanged. Most importantly, this class of compounds does not inhibit Notch processing. As a result, GSMs may be an effective approach to selectively reduce formation of the toxic Aβ peptides while sparing normal enzymatic function (see introduction of the paper for more info along with relevant references). https://lnkd.in/enHskGYp

320

12 Comments

🚀 Join us at the Antibody Therapeutics Xchange - Maryland 2024! 🔬💡 We're excited to highlight Birthe Jessen-Park, Technical Sales Specialist Custom Antibodies at Bio-Rad Laboratories🌟, an industry leader in antibody discovery, who will be presenting at two exciting sessions during this year's event: 📅 Time: 11:20 AM - 12:20 PM ✨ Roundtable Discussion: "The Perfect Workflow for Generating Antibody Drug Candidates" 🧬 Key topics covered include: 🤔 How many hits (binders) should be further analyzed? 🎯 What are the most relevant selection criteria? 🧠 Solving challenges like affinity, developability, and epitope selection. 📅 Time: 3:35 PM - 4:05 PM 🔍 Poster Presentation: "Rapid Generation of Bispecific Antibodies for High Throughput Screening with SpyLock Technology" 🧫 Birthe will introduce SpyLock Technology 🛠️, an innovative approach for creating bispecific antibodies. This technology, compatible with Bio-Rad’s Pioneer™ Antibody Discovery Platform, offers a faster, more efficient path to discovering bispecifics 🔝. With a rich background at Bio-Rad Laboratories, Alloy Therapeutics, and Medimmune, and a PhD from the University of Freiburg 🎓, Birthe brings unparalleled expertise to these sessions. 📍 Location: College Park Marriott, Maryland 🏨 📅 Date: October 28, 2024 Secure your spot and get your complimentary pass! https://lnkd.in/eqyZAeXX 💬 Don't miss this chance to connect with Birthe and other top industry experts! Let's shape the future of antibody therapeutics together! 💼✨ 💊 Only available for Senior Scientists and above, from Bio and Pharma companies with a drug pipeline. #AntibodyTherapeutics #Biopharma #Biotechnology #PharmaInnovation #AntibodyDiscovery #DrugDevelopment #LeadOptimization #BioRad #TherapeuticsXchange #ADC #MultispecificAntibodies #BiopharmaLeaders #ProteinEngineering #BiotechEvents #PharmaIndustry #LifeSciences #TherapeuticInnovation #BiotechNetworking #ScientificResearch #AntibodyEngineering #PharmaCollaboration #NextGenTherapeutics #BioPharmaExperts #PharmaRND #hubXchange #Xchanges #Roundtable #FreePass #RegisterNow #ComplimentaryPass

4

Check out our program selection, and register today! ISPPP.ORG Program Selection Todd Maloney Executive Director in Synthetic Molecule Design and Development, Eli Lilly Process Analytical Technology for Advanced Process Understanding and Control: Case Studies in Synthetic Drug Substance Process Development and Manufacturing Michael L. Gross ​Professor of Chemistry and of Immunology and Internal Medicine (School of Medicine), Washington University in St. Louis Protein Footprinting and Applications for Soluble and Membrane Proteins Oleg Krokhin Associate Professor, Internal Medicine, University of Manitoba, Peptide separation selectivity of reversed-phase C18 separation media for proteomic applications Binchuan Wei Senior Principal Scientist, Synthetic Molecule Chemistry, Genentech Characterization of guide RNA for CRISPR: Methods, Mechanisms and Applications Brian Wei Senior Scientist, Bioprocess Analytics, Sanofi High-Throughput Analytical Assay Development for N-Glycans in Novel Protein-Based Modalities Lance Cadang Principal Scientist, Genentech Native HIC MS of ADCs for DAR species determination and identification To see our ever-growing Preliminary 2024 Program, use the link belowhttps://lnkd.in/e4wxgEhE KEY DATES September 30th, 2024 – Oral and Poster abstract deadline for inclusion in the printed final program October 11th 2024 – Hotel Reservation Deadline October 15th, 2024 – Final date to submit last-minute posters to the online program October 28-30th, 2024 – ISPPP at the Delray Beach #biopharma #peptide #LCMS #chromatography #Conference #purification #separation #Characterization #Analytical #Symposia #Proteomics #Glycomics #MassSpectrometry #Lipid #rna

5

1 Comment

Excited to share the latest feature in our "Partnering Spotlight" series, where we share some of the connections we are building to foster scientific innovation in healthcare. In this edition, our very own Neha Kaushal sits down with Daniel Anderson, Professor of Chemical Engineering at MIT, to discuss the potential of innovative #mRNA applications in vaccines and novel treatments for genetic diseases. Check out the video to learn more about our collaboration! https://lnkd.in/eHwpyjeY #vaccines #immunoscience

40

1 Comment

We are looking for a Scientific Leader with strong expertise in the field of chronic infection and the impact on cells and systems, leading to consequences like neurodegenerative or -inflammatory diseases

28

Catching up on reading and thrilled to share a recent publication linked below. A collaborative effort led by Professor Jack Taunton’s lab at UCSF on an increasingly compelling target, the paper illustrates the subset selective inhibition of Sec61-mediated co-translational translocation of client proteins by KZR-9873 to include the oncoprotein HER3.  This paper not only details sequence selective effects and mechanistic hypotheses but also introduces a method for parallel library screening of over 4000 client signal protein sequences, paving the way for profiling future Sec61 inhibitors. Another modality for small molecule targeting of functional expression of secreted and cell surface proteins. Check it out! https://lnkd.in/g3DGPgUs

40

2 Comments

I’m pleased to share our latest publication in Nature Communications. In this collaborative project with Jun Liu and Scott Johnson at the Mayo Clinic, we report new insights into the function of the wildtype #PNPLA3 enzyme in balancing lipid levels in the liver and bloodstream. These findings add to the broader understanding of biological mechanisms that drive steatotic liver disease, and reinforce our belief in precision medicine approaches to address disease drivers in #MASH. https://lnkd.in/d-a2Kqzc #MASLD, #SLD, #NAFLD, #NASH, #precisionmedicine, #AstraZeneca, #whatsciencecando,Katja Madeyski-Bengtson

135

2 Comments

Novartis has joined forces with Versant Ventures to establish Borealis Biosciences, Inc., an independent biotechnology company based in Vancouver, Canada. This collaboration aims to pioneer next-generation xRNA-based medicines specifically tailored for kidney diseases. With xRNA as a core technology platform, Novartis can precisely target the body's natural mRNA to regulate the production of disease-causing proteins. As part of this partnership, Novartis retains the option to acquire two future development-ready programs, enhancing its renal portfolio – a strategic focus area for the company. Borealis leverages the scientific expertise inherited from Novartis' acquisition of Chinook Therapeutics, a Novartis Company Therapeutics, which bolsters the potential and pace of successful early drug discovery endeavors. #creativefinancing #kidneydisease #advancedtherapies #xRNA #renaldisease #funding #financing #biotech #biotechnology #lifescience #lifesciences #technologyplatform #partnership #bigpharma #renalportfolio3Drugdiscovery

51

1 Comment

Biomanufacturing has immense potential to transform complex, global pharma supply chains into efficient, agile, and resilient domestic supply chains. We have demonstrated the viability of the Antheia, Inc. platform at commercial scale, and with the right investment in domestic biomanufacturing infrastructure, we can onshore critical supply chains, like pharma, back to the U.S.  Today was a career highlight and I look forward to playing a role in the ongoing efforts to develop the infrastructure that will support a robust U.S. biomanufacturing industry.  #Antheia #Biomanufacturing #Biotechnology #Synthetic Biology #Bioeconomy 

41

1 Comment

If you are a leader at a drug development startup, you have to handle complexity every now and then. So, focus is important, as described by Dr. Ankit Mahadevia. Know what to focus on. Tell them what to focus on. Guide them to focus on what to focus on. Make sure each person knows what to focus on. Check whether they focus on what to focus on.

8

Colleagues, a few years ago I sat on a panel to discuss the 'future of chemistry', alongside Nobel Laureate Ben Feringa and Bowen Liu, a super bright doctoral candidate from Stanford. I came to the conclusion, happily, that emerging scientists like Bowen, who have adapted an amazing multi-disciplinary skillset from science and technology, really are the future of chemistry (and life science). I've followed Bowen as his career has progressed and he has definitely reinforced my thinking. I found this recent posting of his to be really interesting, as he discusses with Vijay Pande and Surya Ganguli an area very closely aligned with my interests. Check it out!

28

1 Comment

In this interview, Vikas Gupta, President of CDMO ReciBioPharm, outlines several key trends shaping the biopharma manufacturing landscape, including the rise of nucleic acid-based therapeutics, and the quest for continuous manufacturing. #biologics #biotherapeutics #RNAtherapies #PAT #continuousmanufacturing

39

Hey LinkedIn Fam - Help out Narwhal Bio! As part of the BioTools Innovator competition, Narwhal has put out a 1 min video about what we're building. The video will be part of a number of factors the BTI team of of advisors will use to rank the companies. Please go to Youtube and "Like" the video as exposure counts! https://lnkd.in/gc6zFqGf Please also "Like" this post below to keep it at the top of people's feeds! Thanks everyone!

53

1 Comment

Promising research in fibrosis and SGK1!

12

Roche's three discontinued MAGE-A4 programs appear to have been based on TCR domain molecules. Could CDR-Life Inc.'s CDR404 - a bispecific and bivalent antibody fragment-based T-cell engager (TCE) targeting MAGE-A4 - yield different results? While antibody-based approaches may exhibit higher affinity for their targets than TCR-based approaches, it's important to note that higher affinity doesn't necessarily translate to improved efficacy. CDR404 is currently undergoing Phase 1 clinical trials (NCT06402201). https://lnkd.in/gQw5ziHF

10